65 related articles for article (PubMed ID: 38527998)
1. Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia.
Aung MMK; Mills ML; Bittencourt-Silvestre J; Keeshan K
Mol Oncol; 2021 Sep; 15(9):2253-2272. PubMed ID: 33421304
[TBL] [Abstract][Full Text] [Related]
2. Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.
Karantanos T; Jones RJ
Adv Exp Med Biol; 2019; 1139():153-169. PubMed ID: 31134500
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome free energy can serve as a dynamic patient-specific biomarker in acute myeloid leukemia.
Uechi L; Vasudevan S; Vilenski D; Branciamore S; Frankhouser D; O'Meally D; Meshinchi S; Marcucci G; Kuo YH; Rockne R; Kravchenko-Balasha N
NPJ Syst Biol Appl; 2024 Mar; 10(1):32. PubMed ID: 38527998
[TBL] [Abstract][Full Text] [Related]
4. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M
Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.
Shiba N; Yoshida K; Hara Y; Yamato G; Shiraishi Y; Matsuo H; Okuno Y; Chiba K; Tanaka H; Kaburagi T; Takeuchi M; Ohki K; Sanada M; Okubo J; Tomizawa D; Taki T; Shimada A; Sotomatsu M; Horibe K; Taga T; Adachi S; Tawa A; Miyano S; Ogawa S; Hayashi Y
Blood Adv; 2019 Oct; 3(20):3157-3169. PubMed ID: 31648321
[TBL] [Abstract][Full Text] [Related]
6. Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia.
Jamalpour M; Li X; Cavelier L; Gustafsson K; Mostoslavsky G; Höglund M; Welsh M
Tumour Biol; 2017 Oct; 39(10):1010428317720643. PubMed ID: 28982308
[TBL] [Abstract][Full Text] [Related]
7. A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia.
Jiang F; Mao Y; Lu B; Zhou G; Wang J
Sci Rep; 2021 Jul; 11(1):14657. PubMed ID: 34282207
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia.
Mumme HL; Raikar SS; Bhasin SS; Thomas BE; Lawrence T; Weinzierl EP; Pang Y; DeRyckere D; Gawad C; Wechsler DS; Porter CC; Castellino SM; Graham DK; Bhasin M
Genome Med; 2023 Oct; 15(1):83. PubMed ID: 37845689
[TBL] [Abstract][Full Text] [Related]
9. Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer.
Alkhatib H; Conage-Pough J; Roy Chowdhury S; Shian D; Zaid D; Rubinstein AM; Sonnenblick A; Peretz-Yablonsky T; Granit A; Carmon E; Kohale IN; Boughey JC; Goetz MP; Wang L; White FM; Kravchenko-Balasha N
Mol Cancer; 2024 Jan; 23(1):17. PubMed ID: 38229082
[TBL] [Abstract][Full Text] [Related]
10. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia.
Huang BJ; Smith JL; Farrar JE; Wang YC; Umeda M; Ries RE; Leonti AR; Crowgey E; Furlan SN; Tarlock K; Armendariz M; Liu Y; Shaw TI; Wei L; Gerbing RB; Cooper TM; Gamis AS; Aplenc R; Kolb EA; Rubnitz J; Ma J; Klco JM; Ma X; Alonzo TA; Triche T; Meshinchi S
Nat Commun; 2022 Sep; 13(1):5487. PubMed ID: 36123353
[TBL] [Abstract][Full Text] [Related]
11. Dynamic patterns of microRNA expression during acute myeloid leukemia state-transition.
Frankhouser DE; O'Meally D; Branciamore S; Uechi L; Zhang L; Chen YC; Li M; Qin H; Wu X; Carlesso N; Marcucci G; Rockne RC; Kuo YH
Sci Adv; 2022 Apr; 8(16):eabj1664. PubMed ID: 35452289
[TBL] [Abstract][Full Text] [Related]
12. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update).
Sherman BT; Hao M; Qiu J; Jiao X; Baseler MW; Lane HC; Imamichi T; Chang W
Nucleic Acids Res; 2022 Jul; 50(W1):W216-W221. PubMed ID: 35325185
[TBL] [Abstract][Full Text] [Related]
13. Overcoming resistance to BRAF
Vasudevan S; Flashner-Abramson E; Alkhatib H; Roy Chowdhury S; Adejumobi IA; Vilenski D; Stefansky S; Rubinstein AM; Kravchenko-Balasha N
NPJ Precis Oncol; 2021 Jun; 5(1):50. PubMed ID: 34112933
[TBL] [Abstract][Full Text] [Related]
14. A Dimension Reduction Approach for Energy Landscape: Identifying Intermediate States in Metabolism-EMT Network.
Kang X; Li C
Adv Sci (Weinh); 2021 May; 8(10):2003133. PubMed ID: 34026435
[TBL] [Abstract][Full Text] [Related]
15. The role of various interleukins in acute myeloid leukemia.
Kaser EC; Zhao L; D'mello KP; Zhu Z; Xiao H; Wakefield MR; Bai Q; Fang Y
Med Oncol; 2021 Apr; 38(5):55. PubMed ID: 33835290
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
